
<u>RUSSIA</u> National Research Institution for Public Health, Moscow, Russia +7- 495-917-48-86

institute@niph.ru



Reforms: implementation the referent pricing for medicines from the List of Vital and Essential Drugs
Limiting prices for generics and reproduced biologics

OUT-PATIENT

100 % reim. - for medicines from positive list for Federal ("7 the most expensive nosology", tuberculosis, HIV, vaccines according to National immunization schedule) or Regional State Programs (oncology, 24 rare diseases, rheumatoid arthritis)

100 % reim. - for some vulnerable groups (disabled children till 18 years, adults with disability of I group).

Co-payment: **50%** for some vulnerable groups (unemployed adults with disability of II and III groups); 13% - for all working citizens or their children or other direct relatives from the positive list

IN-PATIENT

100 % reim. for all medicines from the Hospital's Formularies for all patients in the State Hospitals

Reforms: preferential financing the programs of drug's supply at the regional level Creation the registers of patients with rare diseases